ClinicalTrials.gg
CompletedNCT01043094Updated Aug 13, 2012Results posted

Safety, Tolerability, and Pharmacokinetic of Single Dose of Pitavastatin 4 mg in Severe Renal Patients Versus Healthy Adult Volunteers

A Phase 4 interventional study of Pitavastatin 4mg in Severe Renal Impairment, sponsored by Kowa Research Institute, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2012-08-13.

Sponsored by Kowa Research Institute, Inc. (part of Kowa Company, Ltd.) · Phase 4 and Interventional

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
16
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 553 studies in Renal Insufficiency with a site in United States — 40 open to participants now, 57 under way, 3 of them phase 3. Renal Insufficiency · United States.

Enrollment
358th of 468
16 · median 32
Started
2009
with 24 others
Phase 4
44 of 553
1 open now
Registered
148th of 553
by date

Among the 553 studies in Renal Insufficiency with a site in United States, this one is the 358th largest by enrollment of the 468 interventional ones that give a count, is one of 25 that started in 2009, is one of 44 in phase 4, and was the 148th registered.

Renal Insufficiency

1,413 studies on the registry are indexed under Renal Insufficiency; 146 are open to participants now.

Browse Renal Insufficiency studies →

Open to participants now

40 of the 553 studies in Renal Insufficiency with a site in United States are open now. Recruiting first, the newest first:

35 more — sign in →

All 40 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 92 Renal Insufficiency studies recruiting now, 48 (52%) set no upper age limit and 19 (21%) stop at 75 or younger; 8 take children under 18; 15 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 553 studies in Renal Insufficiency with a site in United States, or all of them as a file.
02

Study summary

This is a Phase 4, multicenter, open label, 1 period study. A total of 16 subjects are planned (8 subjects in Group A and 8 subjects in Group B):

The 2 groups will be comparable in terms of age, gender, and body mass index (BMI); the ranges for comparison will be obtained from the pooled demographic data of the renally impaired subjects. The mean age of Group B will be within 5 years of the mean age of Group A, the mean BMI of Group B will be within 18% of the mean BMI of Group A, and the ratio of men to women in Group B will be the same as in Group A.

03

Conditions studied

  • Severe Renal Impairment

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject is an adult male or female subject aged 18 years or older. Females of must have a negative pregnancy test before beginning the study.
  • Subject has no medical conditions (other than renal impairment and associated diseases, such as hypertension, diabetes, and dyslipidemia, for subjects in Group A) as determined by medical history, physical examination, 12-lead , clinical laboratory results (hematology, serum chemistry, and urinalysis [if able to pass urine]), and serology results ( surface antigen, virus antibody, and types 1 and 2 antibody). Subjects with positive results for hepatitis C virus but who have normal liver enzymes will not be excluded. Any subjects who have impaired hepatic function that will potentially affect drug metabolism should be excluded.
  • Subject provides written before any study-specific evaluation is performed.
  • Subject is able and willing to comply with the protocol and study procedures.

Exclusion criteria

Exclusion Criteria:

  • Subject is on maintenance hemodialysis.
  • Subject has a of >37 kg/m2.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 4
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    Pitavastatin 4mg renal impaired

    Subjects with severe renal impairment (glomerular filtration rate \[GFR\] of 15 to 29 mL/min/1.73 m2, inclusive) who are not being treated with hemodialysis

    Drug: Pitavastatin 4mg

  • Active comparator
    Pitavastatin 4mg healthy subjects

    Healthy subjects (GFR greater than or equal to 90 mL/min/1.73 m2)

    Drug: Pitavastatin 4mg

Interventions

06

What researchers measure

Primary outcomes

  1. Area Under the Curve From 0 to Tau (AUC 0-t (ng*h/mL))

    Area under the curve from start to elimination for Pitavastatin.

    Time frame: 48 hours

Secondary outcomes

  1. Number of Participants With Treatment Emergent Adverse Events

    Time frame: 3 Days

07

Results

Posted Aug 13, 2012

Participant flow

Study period was from 23 November 2009 to 07 June 2010 All subjects were seen at a medical clinic

Participant flow — Overall Study
MilestonePitavastatin 4mg Renal ImpairedPitavastatin 4mg Healthy Subjects
Started88
Completed88
Not completed00

Outcome measures

PrimaryArea Under the Curve From 0 to Tau (AUC 0-t (ng*h/mL))

Area under the curve from start to elimination for Pitavastatin.

Time frame:
48 hours
Reported as:
Mean · nanogram hour per milliliter (ng•h/mL)
Area Under the Curve From 0 to Tau (AUC 0-t (ng*h/mL))
nanogram hour per milliliter (ng•h/mL)Pitavastatin 4mg Renal ImpairedPitavastatin 4mg Healthy Subjects
Area Under the Curve From 0 to Tau (AUC 0-t (ng*h/mL))175 ± 39145 ± 55
SecondaryNumber of Participants With Treatment Emergent Adverse Events
Time frame:
3 Days
Reported as:
Number · Participants
Number of Participants With Treatment Emergent Adverse Events
ParticipantsPitavastatin 4mg Renal ImpairedPitavastatin 4mg Healthy Subjects
Number of Participants With Treatment Emergent Adverse Events33

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pitavastatin 4mg Renal Impaired—0/8 (0%)3/8 (37.5%)
Pitavastatin 4mg Healthy Subjects—0/8 (0%)1/8 (12.5%)
Most frequent other events
Most frequent other events
EventPitavastatin 4mg Renal ImpairedPitavastatin 4mg Healthy Subjects
DiarrheaGastrointestinal disorders1/80/8
NauseaGastrointestinal disorders1/80/8
VomitingGastrointestinal disorders1/80/8
FatigueGeneral disorders1/80/8
MyalgiaMusculoskeletal and connective tissue disorders0/81/8
PolyuriaRenal and urinary disorders1/80/8

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Pitavastatin 4mg Renal ImpairedPitavastatin 4mg Healthy SubjectsTotal
<=18 years000
Between 18 and 65 years6814
>=65 years202
Age Continuous
Age Continuous(years)Pitavastatin 4mg Renal ImpairedPitavastatin 4mg Healthy SubjectsTotal
Mean54.1 ± 15.4152.0 ± 2.6253.1 ± 10.74
Sex: Female, Male
Sex: Female, Male(Participants)Pitavastatin 4mg Renal ImpairedPitavastatin 4mg Healthy SubjectsTotal
Female336
Male5510
Region of Enrollment
Region of Enrollment(participants)Pitavastatin 4mg Renal ImpairedPitavastatin 4mg Healthy SubjectsTotal
United States8816
08

Study locations

1 site
  • Minneapolis, Minnesota, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2009, a primary completion of Apr 2010 and a completion of Dec 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2012, 2 years 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 18, 2009
First posted
Jan 6, 2010
Start
Dec 2009
Primary completionActual
Apr 2010
CompletionActual
Dec 2010
Results first posted
Aug 13, 2012
Last update
Aug 13, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 13, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01043094
Responsible party
Sponsor
First posted
Jan 6, 2010
Start date
Dec 2009
Primary completion
Apr 2010
Completion
Dec 2010
Results posted
Aug 13, 2012
Last update
Aug 13, 2012

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pitavastatin

Start the discussion